非酒精性脂肪性肝病的流行病学和危险因素分析

舒筠然; 李俊琪; 刘琼

doi:10.3969/j.issn.1001-5256.2019.09.045

非酒精性脂肪性肝病的流行病学和危险因素分析

DOI: 10.3969/j.issn.1001-5256.2019.09.045

1. 西安市第九医院肾脏内科
2. 西安市第九医院眼科

详细信息

中图分类号: R575.5
计量
- 文章访问数: 1391
- HTML全文浏览量: 45
- PDF下载量: 311
- 被引次数: 0
出版历程
- 收稿日期: 2019-03-13
- 出版日期: 2019-09-20

Epidemiology of nonalcoholic fatty liver disease and related risk factors

Department Nephrology, Ninth Hospital of Xi'an

摘要

摘要: 非酒精性脂肪性肝病(NAFLD)最早的流行病学研究主要集中在西方国家,但越来越多的研究表明NAFLD在亚太地区非常普遍,并且亚太和西方国家之间在表型上可能存在很大区别。肥胖、血脂异常、2型糖尿病已证明是NAFLD发生的危险因素。同时西方国家已经描述了NAFLD的许多其他危险因素(如甲状腺功能减退症、多囊卵巢综合征、阻塞性睡眠呼吸暂停、垂体和性腺机能减退),但这些因素尚未在亚太地区发现其与NAFLD有关。主要讨论了亚太地区特别是中国NAFLD的流行病学和危险因素。
- 脂肪肝 /
- 流行病学 /
- 危险因素
Abstract: The earliest epidemiological studies of nonalcoholic fatty liver disease ( NAFLD) were mainly conducted in Western countries, while more and more studies have shown that NAFLD is very common in the Asia-Pacific region and that there may be great differences in phenotype between the Asia-Pacific and Western countries. Obesity, dyslipidemia, and type 2 diabetes have been shown to be the risk factors for the development of NAFLD. Meanwhile, Western countries have described many other risk factors for NAFLD, such as hypothyroidism, polycystic ovary syndrome, obstructive sleep apnea syndrome, hypopituitarism, and hypogonadism, but these factors have not yet been found to be associated with NAFLD in the Asia-Pacific region.
- fatty liver /
- epidemiology /
- risk factors

HTML全文

参考文献(61)

[1] FARRELL GC, WONG VW, CHITTURI S. NAFLD in Asia-as common and important as in the West[J]. Nat Rev Gastroenterol Hepatol, 2013, 10 (5) :307-318.

[2] LEE SB, KIM KM, AN J, et al. Clinical characteristics and potential aetiologies of non-B non-C hepatocellular carcinoma in hepatitis B virus endemic area[J]. Liver Int, 2016, 36 (9) :1351-1361.

[3] WONG WS, CHU CW, WONG LH, et al. Prevalence of nonalcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese:A population study using proton-magnetic resonance spectroscopy and transient elastography[J].Gut, 2012, 61 (3) :409-415.

[4] WEI JL, LEUNG JC, LOONG TC, et al. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients:A population study using proton-magnetic resonance spectroscopy[J]. Am J Gastroenterol, 2015, 110 (9) :1306-1314.

[5] WONG LH, ESPINOSA WZ, WONG WS. Personalized management of cirrhosis by non-invasive tests of liver fibrosis[J]. Clin Mol Hepatol, 2015, 21 (3) :200-211.

[6] DAS K, DAS K, MUKHERJEE PS, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease[J]. Hepatology, 2010, 51 (5) :1593-1602.

[7] KARIMI-SARI H, MOUSAVI-NAEINI SM, KHONCHE A, et al. Comments on prevalence of non-alcoholic fatty liver disease and its related factors in Iran[J]. Int J Organ Transplant Med, 2017, 8 (1) :52-53.

[8] ZHANG H, HE SM, SUN J, et al. Prevalence and etiology of abnormal liver tests in an adult population in Jilin, China[J].Int J Med Sci, 2011, 8 (3) :254-262.

[9] RAGHUVANSHI T, GARG S, AGGARWAL S, et al. Prevalence of non-alcoholic fatty liver disease in non-obese non-diabetic hypothyroid North Indian population[J]. J Assoc Physicians India, 2016, 64 (1) :37.

[10] DING YP, LI H, ZHANG W, et al. Epidemiological characteristics and risk factors of ALT elevated nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2017, 33 (12) :2355-2360. (in Chinese) 丁玉平, 李海, 张文, 等. ALT升高的非酒精性脂肪性肝病的流行病学特征及其危险因素分析[J].临床肝胆病杂志, 2017, 33 (12) :2355-2360.

[11] LU ZY, SHAO Z, LI YL, et al. Prevalence of and risk factors for non-alcoholic fatty liver disease in a Chinese population:An 8-year follow-up study[J]. World J Gastroenterol, 2016, 22 (13) :3663-3669.

[12] NISHIOJI K, SUMIDA Y, KAMAGUCHI M, et al. Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011-2012[J]. J Gastroenterol, 2015, 50 (1) :95-108.

[13] BRANDON OW, TAN LX, XU ZR. Nonalcoholic fatty liver disease and diabetes mellitus[J]. Clin Focus, 2017, 32 (8) :649-653. (in Chinese) BRANDON OW, 谈力欣, 许樟荣.非酒精性脂肪性肝病与糖尿病[J].临床荟萃, 2017, 32 (8) :649-653.

[14] DUSEJA A, SHARMA B, KUMAR A, et al. Nonalcoholic fatty liver in a developing country is responsible for significant liver disease[J]. Hepatology, 2010, 52 (6) :2248-2249.

[15] CLAUS EB, CHU P, HOWE CL, et al. Pathobiologic findings in DCIS of the breast:Morphologic features, angiogenesis, HER-2/neu and hormone receptors[J]. Exp Mol Pathol, 2015, 70 (3) :303-316.

[16] MELLO T, MATEROZZI M, GALLI A. PPARs and mitochondrial metabolism:From NAFLD to HCC[J]. PPAR Res, 2016, 2016:7403230.

[17] ABE H, KAI Y, KITAHARA T, et al. Etiology of non-B nonC hepatocellular carcinoma in the eastern district of Tokyo[J]. J Gastroenterol, 2008, 43 (12) :967-974.

[18] SANG SL, JEONG SH, BYOUN YS, et al. Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma[J]. Bmc Cancer, 2013, 13 (1) :1-9.

[19] ALEXANDER J, TORBENSON M, WU TT, et al. Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver:A clinical and pathological study[J]. J Gastroenterol Hepatol, 2013, 28 (5) :848-854.

[20] TIAN JH, TANG YX. Relationship between nonalcoholic fatty liver disease and primary liver cancer[J]. Chin J New Med, 2013, 6 (8) :771-776. (in Chinese) 田景绘, 唐艳霞.非酒精性脂肪性肝病与原发性肝癌相关性探讨[J].中国临床新医学, 2013, 6 (8) :771-776.

[21] QIU WG. Clinicopathological features of steatohepatitic hepatocellular carcinoma and its prognosis after resection[D].Fuzhou:Fujian Medical University, 2016. (in Chinese) 邱伟刚.脂肪性肝炎肝细胞癌临床病理特点及切除术后的预后分析[D].福州:福建医科大学, 2016.

[22] ANGULO P. Diagnosing steatohepatitis and predicting liverrelated mortality in patients with NAFLD:Two distinct concepts[J]. Hepatology, 2011, 53 (6) :1792-1794.

[23] DUNN W, SANYAL AJ, BRUNT EM, et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD) [J]. J Hepatol, 2012, 57 (2) :384-391.

[24] PARK SH, JEON WK, KIM SH, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults[J]. J Gastroenterol Hepatol, 2006, 21 (1) :138-143.

[25] KOZLITINA J, BOERWINKLE E, COHEN JC, et al. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance[J]. Hepatology, 2011, 53 (2) :467.

[26] WESTON SR, LEYDEN W, MURPHY R, et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease[J]. Hepatology, 2015, 41:372-379.

[27] KO SH, BAEG MK, JUNG HS, et al. Russian Caucasians have a higher risk of erosive reflux disease compared with East Asians:A direct endoscopic comparison[J]. Neurogastroenterol Motil, 2017, 29 (5) :e13002.

[28] WONG VW, WONG GL, CHOI PC, et al. Disease progression of non-alcoholic fatty liver disease:A prospective study with paired liver biopsies at 3 years[J]. Gut, 2010, 59 (7) :969.

[29] CHITTURI S, WELTMAN M, FARRELL GC, et al. HFE mutations, hepatic iron, and fibrosis:Ethnic-specific association of NASH with C282Y but not with fibrotic severity.[J]. Hepatology, 2002, 36 (1) :142-149.

[30] TIAN NN, LIN XQ, QI YF, et al. Meta-analysis of genetic susceptibility of HFE gene polymorphism and nonalcoholic fatty liver disease[J]. Acad J Guangdong Pharm Coll, 2017, 33 (2) :235-240. (in Chinese) 田娜娜, 林欣琪, 祁永芬, 等. HFE基因多态性与非酒精性脂肪肝病遗传易感性的Meta分析[J].广东药学院学报, 2017, 33 (2) :235-240.

[31] VALENTI L, NOBILI V, AL-SERRI A, et al. The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver[J]. J Hepatol, 2011, 55 (6) :1409-1414.

[32] KOZLITINA J, BOERWINKLE E, COHEN JC, et al. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance[J]. Hepatology, 2011, 53 (2) :467.

[33] NIU TH, JIANG M, LIU HG, et al. Correlation between gene polymorphism of apolipoprotein C3 promoter region and nonalcoholic fatty liver disease[J]. Chin J Hepatol, 2014, 22 (5) :374-379. (in Chinese) 牛同红, 姜曼, 刘昊刚, 等.载脂蛋白C3启动子区基因多态性与非酒精性脂肪性肝病的相关性[J].中华肝脏病杂志, 2014, 22 (5) :374-379.

[34] HAO Y, TIAN XB, LIU TT, et al. MC4R expression in pedunculopontine nucleus involved in the modulation of midbrain dopamine system[J]. Int J Clin Exp Pathol, 2015, 8 (2) :2039-2043.

[35] CHEN KY, MUNIYAPPA R, ABEL BS, et al. RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals[J]. J Clin Endocrinol Metab, 2015, 100 (4) :1639-1645.

[36] CHAMBERS JC, ELLIOTT P, ZABANEH D, et al. Common genetic variation near MC4R is associated with waist circumference and insulin resistance[J]. Nat Genet, 2008, 40 (6) :716-718.

[37] ROMEO S, KOZLITINA J, XING C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease[J]. Nat Genet, 2008, 40 (12) :1461-1465.

[38] LIU JQ, ZHANG ZJ, WANG W, et al. Risk factors for nonalcoholic fatty liver disease in type 2 diabetes in adolescents[J]. World Chin J Dig, 2015, 23 (11) :1812-1817. (in Chinese) 刘建强, 张志坚, 王雯, 等.青少年非酒精性脂肪肝合并2型糖尿病的危险因素[J].世界华人消化杂志, 2015, 23 (11) :1812-1817.

[39] DUSEJA A, BHANSALI A, BHADADA S, et al. Nonalcoholic fatty liver disease in patients with recent onset type 2 diabetes mellitus[J]. J Gastroenterol Hepatol, 2004, 19 (Suppl) :A402.

[40] KALRA S, VITHALANI M, GULATI G, et al. Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT) [J]. J Assoc Physicians India, 2013, 61 (7) :448-453.

[41] WANG HM, LAN MJ. Ultrasound findings of liver in 172 patients with type 2 diabetes mellitus[J]. Capital Food Pharm, 2007, 14 (6) :35. (in Chinese) 王红梅, 兰明娟. 172例2型糖尿病患者肝脏的超声表现[J].首都食品与医药, 2007, 14 (6) :35.

[42] MOHAN V, FAROOQ S, DEEPA M, et al. Prevalence of nonalcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome[J]. Diabetes Res Clin Pract, 2009, 84 (1) :84-91.

[43] YOUNOSSI ZM, STEPANOVA M, RAFIQ N, et al. Pathologic criteria for nonalcoholic steatohepatitis:Interprotocol agreement and ability to predict liver-related mortality[J]. Hepatology, 2011, 53 (6) :1874-1882.

[44] WILLIAMSON RM, PRICE JF, GLANCY S, et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes:The edinburgh type 2 diabetes study[J]. Diabetes Care, 2011, 34 (5) :1139-1144.

[45] FAN JG, LI F, CAI XB, et al. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders[J]. J Gastroenterol Hepatol, 2007, 22 (7) :1086-1091.

[46] HASHIMOTO E, TOKUSHIGE K, FARRELL GC. Histological features of non-alcoholic fatty liver disease:What is important?[J]. J Gastroenterol Hepatol, 2012, 27 (1) :5.

[47] HSIEH SD, YOSHINAGA H, MUTO T, et al. Health risks among Japanese men with moderate body mass index[J]. Int J Obes Relat Metab Disord, 2000, 24 (3) :358-362.

[48] ARGO CK, NORTHUP PG, AL-OSAIMI AM, et al. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis[J]. J Hepatol, 2009, 51 (2) :371-379.

[49] DUSEJA A, DAS A, DHIMAN RK, et al. Indian patients with nonalcoholic fatty liver disease presenting with raised transaminases are different at presentation[J]. World J Gastroenterol, 2007, 13 (4) :649.

[50] HUI JM, HODGE A, FARRELL GC, et al. Beyond insulin resistance in NASH:TNF-alpha or adiponectin?[J]. Hepatology, 2004, 40 (1) :46.

[51] PETERSEN KF, DUFOUR S, FENG J, et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men[J]. Proc Natl Acad Sci U S A, 2006, 103 (48) :18273-18277.

[52] ZHANG ZL, HUANG YS, FAN YD, et al. Effect of Xuezhikang on hepatitis and oxidative stress in rats with nonalcoholic fatty liver disease[J]. Chin J Med Offic, 2018, 46 (6) :605-609. (in Chinese) 张子龙, 黄樱硕, 范煜东, 等.血脂康对非酒精性脂肪性肝病大鼠肝炎症及氧化应激影响[J].临床军医杂志, 2018, 46 (6) :605-609.

[53] LIN YC, CHANG PF, YEH SJ, et al. Risk factors for liver steatosis in obese children and adolescents[J]. Pediatr Neonatol, 2010, 51 (3) :149-154.

[54] MARCHESINI G, FORLANI G. Diabetes and hepatocellular cancer risk:Not only a matter of hyperglycemia[J]. Hepatology, 2012, 55 (4) :1298-1300.

[55] HAMAGUCHI M, KOJIMA T, TAKEDA N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease[J].Ann Intern Med, 2005, 143:722-728.

[56] ISHIBA H, SUMIDA Y, KATAOKA S, et al. Association of coronary artery calcification with liver fibrosis in Japanese patients with NAFLD[J]. Hepatol Res, 2016, 46 (11) :1107-1117.

[57] CLARK JM, BRANCATI FL, DIEHL AM. The prevalence and etiology of elevated aminotransferase levels in the United States[J]. Am J Gastroenterol, 2003, 98 (5) :960-967.

[58] IOANNOU GN. The natural history of NAFLD:Impressively unimpressive[J]. Gastroenterology, 2005, 129 (5) :1805.

[59] WELLS MM, LI Z, ADDEMAN B, et al. Computed tomography measurement of hepatic steatosis:Prevalence of hepatic steatosis in a Canadian population[J]. Can J Gastroenterol Hepatol, 2016, 2016:4930987.

[60] BEDOGNI G, MIGLIOLI L, MASUTTI F, et al. Incidence and natural course of fatty liver in the general population:The dionysos study[J]. Hepatology, 2007, 46 (5) :1387-1391.

[61] CABALLERíA L, PERA G, AULADELL MA, et al. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain[J]. Eur J Gastroenterol Hepatol, 2010, 22 (1) :24-32.

施引文献

资源附件(0)

访问统计